Replies to post #238565 on Biotech Values

[DewDiligence]

OCUP—I’m skeptical of the market size for drugs that merely fix presbyopia for a few hours.

[DewDiligence]

OCUP -29%/AH on phase-2 miss in diabetic retinopathy:

https://finance.yahoo.com/news/ocuphire-announces-topline-results-zeta-210100556.html

In the ZETA-1 Phase 2 trial, APX3330 did not meet the primary endpoint (% of patients with a >= 2-step improvement in DRSS at week 24 in the study eye).

A “key” secondary endpoint relating to each patient’s non-study eye was met.